Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted combination therapy for obstructive sleep apnoea after incomplete response to mandibular advancement splint
ACTRN12618001995268Phase 2Completed
- Sponsor
- Neura Health
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of zolpidem, atomoxetine, oxybutynin and oxygen in obstructive sleep apnea hypopnea syndrome (OSAHS) (3 arms), sponsored by Neura Health. Primary endpoint: Apnoea-hypopnoea index. Started Dec 2018; status: completed.
02
Drugs
zolpidematomoxetineoxybutyninoxygen
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on ACTRN12618001995268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001995268.